[go: up one dir, main page]

BRPI0912927A2 - "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" - Google Patents

"método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"

Info

Publication number
BRPI0912927A2
BRPI0912927A2 BRPI0912927-8A BRPI0912927A BRPI0912927A2 BR PI0912927 A2 BRPI0912927 A2 BR PI0912927A2 BR PI0912927 A BRPI0912927 A BR PI0912927A BR PI0912927 A2 BRPI0912927 A2 BR PI0912927A2
Authority
BR
Brazil
Prior art keywords
individual
independent tumor
vegf
treating
detecting
Prior art date
Application number
BRPI0912927-8A
Other languages
English (en)
Inventor
Ferrara Napoleone
Willis Brandon
Filvaroff Ellen
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BRPI0912927A2 publication Critical patent/BRPI0912927A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" são fornecidos métodos para identificar ou diagnosticar tumor independente de vegfs e métodos para tratar tumor independente de vegfs.
BRPI0912927-8A 2008-08-29 2009-08-28 "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" BRPI0912927A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9316108P 2008-08-29 2008-08-29
US61/093,161 2008-08-29
PCT/US2009/055434 WO2010025414A2 (en) 2008-08-29 2009-08-28 Diagnostics and treatments for vegf-independent tumors

Publications (1)

Publication Number Publication Date
BRPI0912927A2 true BRPI0912927A2 (pt) 2019-10-01

Family

ID=41571323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912927-8A BRPI0912927A2 (pt) 2008-08-29 2009-08-28 "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"

Country Status (13)

Country Link
US (1) US20100055099A1 (pt)
EP (1) EP2321433A2 (pt)
JP (1) JP2012501188A (pt)
KR (1) KR20110068987A (pt)
CN (1) CN102137939A (pt)
AR (1) AR073231A1 (pt)
AU (1) AU2009285540A1 (pt)
BR (1) BRPI0912927A2 (pt)
CA (1) CA2734172A1 (pt)
IL (1) IL211088A0 (pt)
MX (1) MX2011002082A (pt)
TW (1) TW201012935A (pt)
WO (1) WO2010025414A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100135780A (ko) * 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
RU2582964C2 (ru) * 2010-07-19 2016-04-27 Ф.Хоффманн-Ля Рош Аг Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы
WO2012151574A1 (en) * 2011-05-05 2012-11-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
CN103323601B (zh) * 2012-03-22 2016-04-20 北京蛋白质组研究中心 S100a9蛋白检测物在制备筛查肝细胞癌试剂盒中的应用
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN103499694A (zh) * 2013-10-14 2014-01-08 中南大学 检测结直肠癌及其恶性程度的免疫组化试剂盒
WO2015148531A1 (en) * 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US9968688B2 (en) * 2014-11-12 2018-05-15 Verily Life Sciences Llc Shielded targeting agents, methods, and in vivo diagnostic system
CA2966216A1 (en) * 2014-11-14 2016-05-19 Genentech, Inc. Predicting response to a vegf antagonist
US10037603B2 (en) * 2015-05-04 2018-07-31 Siemens Healthcare Gmbh Method and system for whole body bone removal and vascular visualization in medical image data
US11499973B2 (en) 2016-05-17 2022-11-15 Duke University Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
CN107807241A (zh) * 2017-11-03 2018-03-16 太原瑞盛生物科技有限公司 一种血管内表皮生长因子受体1的磁微粒化学发光检测试剂盒及制备方法
US11058345B2 (en) * 2018-07-05 2021-07-13 Boston Scientific Scimed, Inc. Devices, systems, and methods for determining inflammation and/or fibrosis
EP4025910A4 (en) * 2019-09-06 2024-02-07 UT-Battelle, LLC METHODS OF IMMUNOREGULATION BY MODULATING PLASMINOGEN-APPLE-NEMATODE DOMAIN (PAN) PROTEINS
WO2021207365A1 (en) * 2020-04-07 2021-10-14 The Wistar Institute Of Anatomy And Biology Reawakening of dormant tumor cells by modified lipids derived from stress activated neutrophils
CN111583992B (zh) * 2020-05-11 2023-08-29 广州金域医学检验中心有限公司 Rna水平融合基因突变导致肿瘤的负荷分析系统和方法
CN114958758B (zh) * 2021-02-18 2024-04-23 南京启真基因工程有限公司 一种乳腺癌模型猪的构建方法及应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
NZ500078A (en) * 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
DE60042021D1 (de) * 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
DE60128685T2 (de) * 2000-06-23 2009-03-05 Bayer Schering Pharma Aktiengesellschaft Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
PE20030062A1 (es) * 2001-05-30 2003-02-08 Sugen Inc Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
KR100883731B1 (ko) * 2001-06-22 2009-02-12 기린 파마 가부시끼가이샤 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
EP1463507A1 (en) * 2001-12-19 2004-10-06 SmithKline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US6790852B2 (en) * 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
JP2006503864A (ja) * 2002-10-01 2006-02-02 ジヨンソン・アンド・ジヨンソン・フアーマシユーチカル・リサーチ・アンド・デベロツプメント・インコーポレーテツド タンパク質チロシンキナーゼ阻害剤としての４，６−ジアミノ置換−２−［オキシ又はアミノキシ］−［１，３，５］トリアジン
CN103265477B (zh) * 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
CA2522595A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20050186208A1 (en) * 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
WO2005005378A2 (en) * 2003-07-02 2005-01-20 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005016920A1 (en) * 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
AU2004284420A1 (en) * 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
US7626030B2 (en) * 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CA2647430A1 (en) * 2006-03-29 2007-10-11 Genentech, Inc. Diagnostics and treatments for tumors

Also Published As

Publication number Publication date
EP2321433A2 (en) 2011-05-18
CA2734172A1 (en) 2010-03-04
AR073231A1 (es) 2010-10-20
AU2009285540A1 (en) 2010-03-04
TW201012935A (en) 2010-04-01
WO2010025414A3 (en) 2010-05-14
KR20110068987A (ko) 2011-06-22
WO2010025414A2 (en) 2010-03-04
JP2012501188A (ja) 2012-01-19
CN102137939A (zh) 2011-07-27
MX2011002082A (es) 2011-06-20
US20100055099A1 (en) 2010-03-04
IL211088A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BRPI0912927A2 (pt) "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
BRPI0915240A2 (pt) método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met
CY1115439T1 (el) Μεθοδοι και νουκλεϊκα οξεα για αναλυσεις διαταραχων του κυτταρικου πολλαπλασιασμου
EP2260109A4 (en) MICRORNA BASED METHOD AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES RELATED TO THE PROSTATE
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
PT3185012T (pt) Método para identificação, seleção e análise de células tumorais
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
ATE410524T1 (de) Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
DE602004005485D1 (de) Verfahren zum beurteilen der nutzungserlaubnis für informationen und inhaltsverbreitungssystem, das dieses verfahren verwendet
EP1788938A4 (en) SYSTEM, SOFTWARE AND METHOD FOR DETECTING RESPIRATORY DISORDERS DURING SLEEP USING AN ELECTROCARDIOGRAM
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
MX2010010746A (es) Composiciones y metodos para tratar y diagnosticar asma.
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
BRPI0918739A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.
BRPI0910030A2 (pt) método de teste ultra-sônico e equipamento para o mesmo.
DE602008006254D1 (de) Doppel-oligonukleotid-nukleinsäurenachweisverfahren
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
GB0704429D0 (en) Method and apparatus for determining information concerning the identity of an individual
EP2227756A4 (en) SYSTEM, METHOD AND SOFTWARE TO SEARCH, ANALYZE AND COMPARE EXPERT WITNESSES
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]